REGENXBIO Reports Third Quarter 2026 Financial Results and Operational
REGENXBIO Inc. (RGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights • RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 • Topline data from pivotal subretinal wet AMD studies, ATM
How this was made
The 30-second read
Why it matters
The cash guidance may reduce near‑term financing risk, but revenue contraction may keep the stock volatile.
Market read
First‑hand disclosure of cash runway and trial milestones offers fresh data for biotech investors.
What to watch
Potential impact of upcoming AMD and Duchenne trial readouts on future valuation.
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
Third-quarter revenue was lower than the prior-year period following the expiration of licensed U.S. patents for ZOLGENSMA, while R&D expense increased. The net loss improved following a litigation-settlement gain, cash increased following an AbbVie milestone and public offering, and the company retained a stated runway into late Q4 2027 while approaching several clinical and regulatory milestones.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30GAAP | $9.2M | – | – |
| License and royalty revenue, three months ended September 30GAAP | $5.24M | – | – |
| Service revenue, three months ended September 30GAAP | $3.92M | – | – |
| ITVISMA royalty revenues, third quarter of 2026GAAP | $2.8M | – | – |
| Cost of license and royalty revenues, three months ended September 30GAAP | $1.14M | – | – |
| Research and development expenses, three months ended September 30GAAP | $61M | – | – |
| General and administrative expenses, three months ended September 30GAAP | $20.6M | – | – |
| Gain on litigation settlement, third quarter of 2026GAAP | $38M | – | – |
| Other operating expenses (income), three months ended September 30GAAP | −$7K | – | – |
| Total operating expenses, three months ended September 30GAAP | $44.70M | – | – |
| Loss from operations, three months ended September 30GAAP | −$35.53M | – | – |
| Interest income from licensing, three months ended September 30GAAP | $16K | – | – |
| Investment income, three months ended September 30GAAP | $2.25M | – | – |
| Interest expense, three months ended September 30GAAP | −$7.47M | – | – |
| Total other income (expense), three months ended September 30GAAP | −$5.20M | – | – |
| Net loss, three months ended September 30GAAP | $40.7M | – | – |
| Net loss per share, basic and diluted, three months ended September 30GAAP | $0.62 basic and diluted net loss per share | – | – |
| Weighted-average common shares outstanding, basic and diluted, three months ended September 30GAAP | 65.26M | – | – |
| Total revenues, nine months ended September 30GAAP | $123.6M | – | – |
| Research and development expenses, nine months ended September 30GAAP | $174.4M | – | – |
| General and administrative expenses, nine months ended September 30GAAP | $63.50M | – | – |
| Loss from operations, nine months ended September 30GAAP | −$89.63M | – | – |
| Net loss, nine months ended September 30GAAP | −$108.1M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30GAAP | $ (1.90) | – | – |
| Weighted-average common shares outstanding, basic and diluted, nine months ended September 30GAAP | 56.88M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| License and royalty revenueZOLGENSMA royalty revenues decreased by $21.2 million due primarily to the expiration of licensed patents in the U.S. in January 2026; the decrease was partially offset by ITVISMA royalty revenues of $2.8 million. | $5.24M | – | – |
| Service revenueNo driver provided. | $3.92M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Cash runway outlook
- NoteCash, cash equivalents and marketable securities of $251.0 million as of September 30, 2026, along with the $39.0 million settlement proceeds received in October 2026, are sufficient to fund operations into late Q4 2027.
- NoteRGX-202 BLA submission is on track for Q1 2027 under the accelerated approval pathway, supporting potential approval in 2H 2027.
- NoteTopline data from the ATMOSPHERE and ASCENT pivotal trials of sura-vec are expected in Q4 2026.
- NoteGlobal regulatory submissions for sura-vec for wet AMD are expected in 2027.
- NoteAFFINITY RISE is expected to initiate in 1H 2027.
What drove it
- The decline in third-quarter revenue was primarily attributable to lower ZOLGENSMA royalty revenues after the expiration of licensed U.S. patents in January 2026.
- ITVISMA royalty revenues were $2.8 million in the third quarter of 2026; Novartis launched U.S. sales in the first quarter of 2026.
- R&D expense increased primarily due to clinical trial expenses for RGX-202.
- The $38.0 million gain on litigation settlement related to a settlement agreement with Sarepta Therapeutics resolving all patent litigation matters between the parties.
- AbbVie paid a $100.0 million milestone in July 2026 for dosing the first patient in the Phase IIb/III NAAVIGATE study.
Concerns
- ZOLGENSMA royalty revenues decreased by $21.2 million due primarily to the expiration of licensed patents in the U.S. in January 2026.
- RGX-121 remains on clinical hold after the FDA's discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study.
- R&D expenses were $61.0 million for the three months ended September 30, 2026, compared to $56.1 million for the three months ended September 30, 2025.
- The cash-runway guidance excludes potential material partner or licensee payments and excludes additional potential dilutive or non-dilutive funding opportunities.
What to watch
- Topline data from the ATMOSPHERE and ASCENT pivotal wet AMD trials expected in Q4 2026.
- The expected pre-BLA meeting for RGX-202 in Q4 2026 and planned BLA submission in Q1 2027.
- Potential accelerated approval of RGX-202 in 2H 2027.
- Enrollment progress in the Phase IIb/III NAAVIGATE trial for diabetic retinopathy.
- Additional imaging and long-term follow-up data for RGX-121 following the FDA clinical hold.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $251.0 million as of September 30, 2026, compared to $240.9 million as of December 31, 2025.
- Cash and cash equivalents were $ 95,795 (in thousands) as of September 30, 2026, compared to $ 34,466 (in thousands) as of December 31, 2025.
- Marketable securities were $ 155,181 (in thousands) as of September 30, 2026, compared to $ 195,604 (in thousands) as of December 31, 2025.
- The cash-position increase was primarily attributable to a $100.0 million milestone payment received from AbbVie in July 2026 and net proceeds of $107.8 million from an underwritten public offering completed in July 2026.
- Cash, cash equivalents and marketable securities as of September 30, 2026 excludes a $39.0 million payment received in October 2026 pursuant to a settlement agreement with Sarepta Therapeutics.
- Total assets were $ 466,040 (in thousands) as of September 30, 2026, compared to $ 453,032 (in thousands) as of December 31, 2025.
- Total liabilities were $ 317,998 (in thousands) as of September 30, 2026, compared to $ 350,299 (in thousands) as of December 31, 2025.
- Royalty monetization liabilities were $ 12,114 (in thousands) current and $ 173,564 (in thousands) non-current as of September 30, 2026.
Analysis
Third-quarter revenue was $9.2 million, compared to $29.7 million in the prior-year period. The release attributes the decline primarily to a $21.2 million decrease in ZOLGENSMA royalty revenue following the January 2026 expiration of licensed U.S. patents. ITVISMA royalty revenues of $2.8 million partly offset that pressure, following Novartis' U.S. launch in the first quarter of 2026.
R&D expense increased to $61.0 million from $56.1 million, primarily due to RGX-202 clinical trial expense, while G&A was described as consistent at $20.6 million versus $20.3 million. The quarter included a $38.0 million litigation-settlement gain tied to Sarepta. Net loss was $40.7 million, or $0.62 basic and diluted net loss per share, versus $61.9 million, or $1.20 per share, in the prior-year quarter.
Cash, cash equivalents and marketable securities were $251.0 million at September 30, 2026, compared with $240.9 million at December 31, 2025. The company cited the $100.0 million AbbVie NAAVIGATE milestone and $107.8 million of net public-offering proceeds as primary sources of the increase, partly offset by cash used in operating activities during the nine months. The September cash balance excludes the $39.0 million Sarepta payment received in October, and management stated that these resources are sufficient to fund operations into late Q4 2027.
Near-term execution centers on pivotal sura-vec wet AMD data from ATMOSPHERE and ASCENT expected in Q4 2026, the RGX-202 pre-BLA meeting in Q4 2026 and planned BLA submission in Q1 2027. The release also identifies the FDA clinical hold on RGX-121 as an outstanding program risk while the company collects and evaluates additional imaging and long-term follow-up data. The key operating tension is replacing declining ZOLGENSMA royalty revenue while funding late-stage development and advancing the stated regulatory timelines.
Management, verbatim
We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028.
Curran Simpson, President and Chief Executive Officer of REGENXBIO
With topline pivotal data expected this quarter, sura-vec has the potential to transform the treatment paradigm for a broad spectrum of patients with wet AMD.
Curran Simpson, President and Chief Executive Officer of REGENXBIO
We also remain on track for the RGX-202 BLA submission early next year as we work toward delivering this important therapy to Duchenne patients as quickly as possible.
Curran Simpson, President and Chief Executive Officer of REGENXBIO
Not in the filing
stated, not guessed- Non-GAAP financial measures were not reported.
- Gross profit and gross margin were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Share repurchases and dividends were not reported.
- A debt balance was not reported.
- Prior-quarter comparisons were not reported for the reported income-statement metrics.
- Percentage year-over-year changes were not reported for the reported income-statement metrics.
- Prior outlook was not provided, so comparison with prior guidance is unavailable.
- Revenue by clinical program or geographic segment was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SEC Form 8‑K provides REGENXBIO's quarterly financials, cash position, and forward‑looking cash guidance.
Ticker impact
REGENXBIO filed its Q3 2026 results showing cash of $251M and guidance that funds operations into late Q4 2027.
potential modest upside as investors price in sufficient cash and upcoming trial data, but pressure from lower revenues.
Guidance confirms enough liquidity for 2027, yet revenue fell sharply; market may react cautiously.
Market effects
Highlights continued investment in gene‑therapy biotech, may boost peer interest.
US biotech sector sees mixed signals from cash strength versus revenue drop.
Limited to investors tracking gene‑therapy pipelines worldwide.
Counterpoint
Revenue decline could signal deeper demand issues, outweighing cash runway optimism.
Key entities
- companyREGENXBIO Inc.
Nasdaq‑listed gene‑therapy developer.
